SCHEMBL1259198

SCHEMBL1259198

CC(=O)Nc1ccc(SCC(C)(O)c2nc3cc(Cl)c(Cl)cc3n2C)cc1

nearest known ligand 0.41

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 2/20 0.39
▸ ACSS2 Q9NR19 1/20 0.38
▸ LMNA P02545 3/20 0.37
▸ PRSS12 P56730 1/20 0.37
▸ RAB9A P51151 2/20 0.37
▸ GFER P55789 1/20 0.37
▸ NPC1 O15118 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ POLB P06746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1258368 0.71 ACSS2 (0.36) GAAACSS2LMNARAB9ANPC1
SCHEMBL1259848 0.71 PRSS12 (0.32) ACSS2LMNAPRSS12
SCHEMBL1260398 0.70 ACSS2 (0.41) GAAACSS2LMNARAB9ANPC1
SCHEMBL10238329 0.65 ACSS2 (0.52) GAAACSS2RAB9ANPC1ALDH1A1
SCHEMBL9518238 0.62 GAA (0.71) GAALMNARAB9AGFERNPC1
SCHEMBL6033907 0.61 GAA (0.69) GAALMNARAB9ANPC1ALDH1A1
SCHEMBL8685308 0.60 GAA (0.63) GAALMNARAB9AGFERNPC1
SCHEMBL15000607 0.59 NPC1 (0.57) LMNARAB9ANPC1ALDH1A1POLB
SCHEMBL14544623 0.59 KMT2A (0.61) GAALMNARAB9ANPC1ALDH1A1
SCHEMBL10927168 0.59 GAA (0.56) GAALMNARAB9AGFERNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1812406-B1 NOVEL BENZIMIDAZOLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) JANSSEN PHARMACEUTICA NV (BE) 2018-09-12 — — EP disclosed
EP-1805147-B1 NOVEL BENZIMIDAZOLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) JANSSEN PHARMACEUTICA NV (BE) 2014-08-13 — — EP disclosed
EP-1805147-B1 NOVEL BENZIMIDAZOLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) JANSSEN PHARMACEUTICA NV (BE) 2014-08-13 — — EP disclosed
US-8586616-B2 Benzimidazole derivatives useful as selective androgen receptor modulators (SARMS) JANSSEN PHARMACEUTICA, NV (BE) 2013-11-19 — — US disclosed
US-20110086883-A1 NOVEL BENZIMIDAZOLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) NG RAYMOND 2011-04-14 — — US disclosed
US-20110086883-A1 NOVEL BENZIMIDAZOLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) NG RAYMOND 2011-04-14 — — US disclosed
US-7879895-B2 prepared by mixing 1-(5,6-dichloro-1H-benzimidazol-2-yl)-2,2,2-trifluoro-ethanol with a carrier; non-steroidal agonists and antagonists; anticarcinogenic agents prostates; alopecia; eating disorders; acne; AIDS; cachexia JANSSEN PHARMACEUTICA NV (BE) 2011-02-01 — — US disclosed
US-7879895-B2 prepared by mixing 1-(5,6-dichloro-1H-benzimidazol-2-yl)-2,2,2-trifluoro-ethanol with a carrier; non-steroidal agonists and antagonists; anticarcinogenic agents prostates; alopecia; eating disorders; acne; AIDS; cachexia JANSSEN PHARMACEUTICA NV (BE) 2011-02-01 — — US disclosed
US-7879895-B2 prepared by mixing 1-(5,6-dichloro-1H-benzimidazol-2-yl)-2,2,2-trifluoro-ethanol with a carrier; non-steroidal agonists and antagonists; anticarcinogenic agents prostates; alopecia; eating disorders; acne; AIDS; cachexia JANSSEN PHARMACEUTICA NV (BE) 2011-02-01 — — US disclosed
US-20100324095-A1 PHARMACEUTICAL COMPOSITION FOR INHIBITING AMYLOID-BETA PROTEIN ACCUMULATION SUMITOMO CHEMICAL COMPANY, LIMITED 2010-12-23 — — US disclosed
US-7566733-B2 Benzimidazole derivatives useful as selective androgen receptor modulators (sarms) JANSSEN PHARMACEUTICA N.V. (BE) 2009-07-28 — — US disclosed
US-7566733-B2 Benzimidazole derivatives useful as selective androgen receptor modulators (sarms) JANSSEN PHARMACEUTICA N.V. (BE) 2009-07-28 — — US disclosed
US-20080119522-A1 5,6-dichloro-2-(2,2,2-trifluoro-ethyl)-1H-benzimidazole for example; use for prostate cancer, benign prostatic hyperplasia (BPH), hirsutism, alopecia, anorexia nervosa, breast cancer, acne, AIDS, cachexia, as a male contraceptive, and/or as a male performance enhancer NG RAYMOND 2008-05-22 — — US disclosed
US-20080119522-A1 5,6-dichloro-2-(2,2,2-trifluoro-ethyl)-1H-benzimidazole for example; use for prostate cancer, benign prostatic hyperplasia (BPH), hirsutism, alopecia, anorexia nervosa, breast cancer, acne, AIDS, cachexia, as a male contraceptive, and/or as a male performance enhancer NG RAYMOND 2008-05-22 — — US disclosed
US-20080119522-A1 5,6-dichloro-2-(2,2,2-trifluoro-ethyl)-1H-benzimidazole for example; use for prostate cancer, benign prostatic hyperplasia (BPH), hirsutism, alopecia, anorexia nervosa, breast cancer, acne, AIDS, cachexia, as a male contraceptive, and/or as a male performance enhancer NG RAYMOND 2008-05-22 — — US disclosed
US-7348438-B2 Benzimidazole derivatives useful as selective androgen receptor modulators (SARMS) JANSSEN PHARMACEUTICA N.V. (BE) 2008-03-25 — — US disclosed
US-7348438-B2 Benzimidazole derivatives useful as selective androgen receptor modulators (SARMS) JANSSEN PHARMACEUTICA N.V. (BE) 2008-03-25 — — US disclosed
US-7348438-B2 Benzimidazole derivatives useful as selective androgen receptor modulators (SARMS) JANSSEN PHARMACEUTICA N.V. (BE) 2008-03-25 — — US disclosed
US-20060116412-A1 Novel benzimidazole derivatives useful as selective androgen receptor modulators (sarms) JANSSEN PHARMACEUTICA N.V. (BE) 2006-06-01 — — US disclosed
US-20060111402-A1 Novel benzimidazole derivatives useful as selective androgen receptor modulators (SARMS) JANSSEN PHARMACEUTICA N.V. (BE) 2006-05-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110086883-A1 NOVEL BENZIMIDAZOLE DERIVATIVES USEFUL AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AR, NR5A1, ESRRA GAA 2241/4885ACSS2 396/4885LMNA 3422/4885
US-20100324095-A1 PHARMACEUTICAL COMPOSITION FOR INHIBITING AMYLOID-BETA PROTEIN ACCUMULATION APP, PSEN1, APBA1 GAA 173/4885ACSS2 1160/4885LMNA 904/4885
US-20060111402-A1 Novel benzimidazole derivatives useful as selective androgen receptor modulators (SARMS) AR, NR5A1, ESRRA GAA 2241/4885ACSS2 396/4885LMNA 3422/4885
US-20080119522-A1 5,6-dichloro-2-(2,2,2-trifluoro-ethyl)-1H-benzimidazole for example; use for prostate cancer, benign prostatic hyperplasia (BPH), hirsutism, alopecia, anorexia nervosa, breast cancer, acne, AIDS, cachexia, as a male contraceptive, and/or as a male performance enhancer AR, FSHR, BRDT GAA 1683/4885ACSS2 640/4885LMNA 4079/4885
US-20060116412-A1 Novel benzimidazole derivatives useful as selective androgen receptor modulators (sarms) AR, NR5A1, ESRRA GAA 2241/4885ACSS2 396/4885LMNA 3422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback